Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth
Woman and Man Max 99 years
Wyeth Pharmaceuticals B.V. (The Netherlands)
Update Il y a 4 ans
Recurrent cutaneous squamous cell carcinoma under Rapamune®
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
Estudio de fase 2, aleatorizado y abierto, de bosutinib administrado en combinación con exemestano frente a exemestano solo como tratamiento de segunda línea en mujeres posmenopáusicas con cáncer de mama RE+/RPg+/ErbB2- localmente avanzado o metastático
The primary objective is to compare efficacy, as measured by PFS and assessed by an independent radiology read, of bosutinib in combination with exemestane with that of exemestane alone.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Kabushiki Kaisha (Wyeth K.K.)
Update Il y a 4 ans
Safety and Efficacy Study of the long-term administration of TNR-001 in Subjects with Juvenile Idiopathic Arthritis (JIA)
Assess the safety of the long-term administration of TNR-001 in subjects with active polyarticular-course JIA.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer
For part 1, the primary objective is to assess the safety and tolerability, and to determine the MTD(s) of bosutinib plus capecitabine in patients with locally advanced or metastatic breast cancer or ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain Estudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral
The objective of this study is to evaluate the efficacy and safety of sub-cutaneous methylnaltrexone in relieving opioid-induced constipation in subjects with cancer-related pain.
Country
None
organs
None
Specialty
None
unknown
More information
Woman
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
WYETH ExteNET : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité du neratinib, après un traitement par trastuzumab, chez des patientes ayant un cancer du sein HER2+. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité d’un traitement par du neratinib après un traitement par du trastuzumab, chez les patientes ayant un cancer du sein HER2+. Les patientes seront répa...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
To evaluate the efficacy of bazedoxifene acetate 20 mg and bazedoxifene acetate 40 mg in comparison to placebo in reduction of new vertebral fractures in osteoporotic postmenopausal women after 36 mon...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company
Update Il y a 4 ans
A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
to compare the investigator assessed progression-free survival (PFS) following treatment with single agent neratinib versus lapatinib plus capecitabine in subjects with erbB2 positive locally advanced...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals B.V. (The Netherlands)
Update Il y a 4 ans
Analyses of PAThogen and HOSt determinants in hospitalised patients with a laboratory confirmed infection caused by Staphylococcus aureus: the PATHOS study
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 3, Randomized, Active-controlled, Double-Blind Trial of the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given in a 2-, 3-, 4- and 11- to 12-Months Schedule With Routine Pediatric Vaccinations
- To demonstrate that the immune responses to the 7 common pneumococcal conjugates induced by 13vPnC are noninferior to the immune responses induced by 7vPnC when measured 1 month after the infant ser...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next